Idex Corporation · NYSE:IEX

Idex — Q2 2023 Earnings Presentation

22 slides from Idex's earnings presentation, Jul 27, 2023

  1. Slide 1: Second Quarter 2023 Earnings

    1 Second Quarter 2023 Earnings July 27, 2023

  2. Slide 2: Agenda

    2IDEX Proprietary & Confidential Agenda IDEX Business Update Q2 2023 Financial Performance Segment Performance 2023 Guidance Summary Closing Remarks Q&A

  3. Slide 3: Replay Information

    3IDEX Proprietary & Confidential Replay Information • Dial toll–free: 877.660.6853 • International: 201.612.7415 • Conference ID: #13734463 • Log on to: www.idexcorp.com

  4. Slide 4: Cautionary Statement

    4IDEX Proprietary & Confidential Cautionary Statement Cautionary Statement Under the Private Securities Litigation Reform Act; Non-GAAP Measures This presentation contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These state

  5. Slide 5: IDEX Business Update

    5IDEX Proprietary & Confidential Business Update

  6. Slide 6: IDEX Overview

    6IDEX Proprietary & Confidential IDEX Overview Second Quarter Results: • Record sales and Adjusted EPS • Growth across FMT/FSD; HST markets remain challenged • Completed acquisition of Iridian Spectral Technologies Looking Ahead: • Industrial downturn and softening HST key markets • Revised full yea

  7. Slide 7: Financials

    7IDEX Proprietary & Confidential Financials

  8. Slide 8: IDEX Q2 2023 Financial Performance

    8IDEX Proprietary & Confidential $97 $120 Q2'22 Q2'23 IDEX Q2 2023 Financial Performance Strong Revenue, Earnings, and Free Cash Flow (Dollars in millions, excl. EPS) *This presentation contains non‐GAAP financial information. Reconciliations of non‐GAAP measures are included either in this presenta

  9. Slide 9: IDEX Q2 2023 Adjusted EBITDA Walk

    9IDEX Proprietary & Confidential Q2 2023 Adjusted EBITDA Walk Strong price/cost and variable compensation more than offset volume headwinds (Dollars in millions) *This presentation contains non‐GAAP financial information. Reconciliations of non‐GAAP measures are included either in this presentation

  10. Slide 10: IDEX 2Q 2023 Segment Performance

    10 Organic Orders V%* 2% Organic Sales V%* 8% Adj EBITDA Margin vbps* +300 Organic Orders V%* (27%) Organic Sales V%* (6%) Adj EBITDA Margin vbps* (420) Organic Orders V%* (4%) Organic Sales V%* 10% Adj EBITDA Margin vbps* +340 Fluid & Metering Technology Health & Science Technology Fire & Safety /

  11. Slide 11: 2023 Guidance Summary

    11IDEX Proprietary & Confidential Third Quarter Full Year Current Guidance Prior Guidance Current Guidance Revenue% vs. Prior Year Organic* (8%) - (7%) 0-3% (2%) - (1%) Adjusted EBITDA%* ~27% 27.5% - 27.9% ~27% Earnings per Share Reported $1.60 - $1.65 $7.30 - $7.60 $6.80 - $6.90 Adjusted* $1.84 - $

  12. Slide 12: IDEX Portfolio Positioned for Growth

    IDEX PROPRIETARY & CONFIDENTIAL IDEX Portfolio Positioned for Growth 12 Sustainable Growth Outperformance Best Organic Opportunities 8020 Dynamic Resourcing Complementary M&A DEMOGRAPHIC SHIFTS INDUSTRY 4.0 & DIGITIZATION SUSTAINABILITY EVOLVING GLOBAL DYNAMICS TOP ORGANIC GROWTH BETS + + 12

  13. Slide 13: Appendix

    13IDEX Proprietary & Confidential Appendix

  14. Slide 14: Fluid & Metering Technologies

    14IDEX Proprietary & Confidential Fluid & Metering Technologies Q2 Highlights:  Slowing Industrial Orders  Strong Water, Energy, and Chemical performance  Mixed Agriculture on high inventory levels and delayed planting season  Strong price-cost and volume leverage driving margin expansion Strong

  15. Slide 15: Health & Science Technologies

    15IDEX Proprietary & Confidential Health & Science Technologies Q2 Sales Mix: Organic (6%) Acquisition 10% FX 0% Reported Sales 4% Q2 Highlights:  Pressure across Analytical Instrumentation and Life Science Markets  Soft Semiconductor, Weak Pharma, Biopharma, Food  Unfavorable volume leverage, mi

  16. Slide 16: Fire & Safety / Diversified Products

    16IDEX Proprietary & Confidential Fire & Safety / Diversified Products Strong revenue growth and margin expansion Q2 Sales Mix: Organic 8% FX 0% Reported Sales 8% (Dollars in millions) *This presentation contains non‐GAAP financial information. Reconciliations of non‐GAAP measures are included eithe

  17. Slide 17: Non-GAAP Reconciliations

    17IDEX Proprietary & Confidential Non-GAAP Reconciliations

  18. Slide 18: �        !" #$%!&'!&!% """ !&'!"(!"&&#"!…

    �        !" #$%!&'!&!% """ !&'!"(!"&&#"!)!&!% )%&&"*!"+!"*,"" '-!&./--012 #%" &"!/--0'!&!%'&"!& (!"3/--0'!&!%'&"!& 2

  19. Slide 19: �             

    �                  !""#$%& '(%)")*+%",-. /01#$%& '(%)")*+%",-.2-2, 2-22 2-2, 2-223!#039;'4!$50& 6 ,789- : ;<=>? 6 7@-9A : =??>BCDE0!FEG+"0%F"%&$!H'&"4I+4J E!K"'  L  M>B  L  M>BN)O+'&")K!#039;'4!$50& 6 ,789-

  20. Slide 20: �             

    �                            !"# $%&$ !''# (%)*+ , -     ..  !/ 0%01 !' 0%01+�.,  , -     ..  2! 3 40%0$5 2! 3

  21. Slide 21: �      � �     � �

    �      � �     � �       ! " # " # " # " # "$%& ' ( ' ( ' ( ' ( ')*+,-./ 0 !   #  #  #  # %&  (  (  (  ( *1,2.      #  #  #  # 3&4  (  (

  22. Slide 22: �        �     !"#$%&'()*#+$,"%+-(+./.0

    �        �     !"#$%&'()*#+$,"%+-(+./.0 1"23(%+./.04567&$ 8#9*7&$ 4567&$ 8#9*7&$:(;5+-($&(-#&'5<( = >?>@A = >?B@C = C>D@D = C?B@>EF+5G#H#5&I5+#&'5<(-%J(H  AC@K  AD@K  >BL@L  >C>@KEM&-(+(H-(J;(&H(  >B@K

Idex — Q2 2023 Earnings Presentation on 6ix